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Abstract
Introduction: Prosthetic graft infection is a major complication of vascular surgery associated 
with high morbid-mortality rates. This retrospective non-randomized single center study 
evaluated our experience in the management of prosthetic vascular graft infections. 
Methods: We review the clinical files of patients who had vascular grafts implanted at our 
center between June 2007 and December 2011 and analysed the cases that developed Samson 
group 3, 4 and 5 infections until December 2012.
Results: From June 2007 to December 2012, 18 consecutive patients (14 males, 4 females) 
with median age 70 years were admitted to our institution with the diagnosis of vascular graft 
infection accounting for an incidence of 3.8%. 50% of these infections were early infections 
and MRSA was the most prevalent pathogen. 44% of infections were due to infection of a 
femoro-popliteal bypass. Using Samson classiÀ cation, 72% were group 4 and 5 infections. We 
performed graft preservation in one patient, graft excision without revascularization in 50% 
(nine) patients; Excision + insitu replacement in 39% (seven) patients; Excision + Extra-anatomic 
bypass in one patient. Our amputation rate was 55% and our related death rate was 16%.
Conclusions: Our amputation and mortality rates are according the published reviews. Besides 
allowing recognition of our reality this offers the opportunity to review diagnosis and therapeutic 
issues in prosthetic vascular graft infections. Each situation needs to be individualized as there 
is no consensus nor guiding algorithms about what should be the best medical treatment.
© 2014 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Published by Elsevier España, S.L. 
All rights reserved.
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Introduction
Prosthetic vascular graft infections (PVGI) are a catastrophic 
event associated with high morbidity and mortality rates.1 It´ s 
incidence ranges between 1 and 6%. The death rate ranges 
between 15 to 75% with a rate of major amputation that may 
reach 70%.2 Staphylococcus species are the most commonly 
implicated causative organisms,3 with Staphylococcus 
aureus more likely in early infection and coagulase-negative 
staphylococci such as Staphylococcus epidermidis more 
likely in late infections.4 The diagnosis of vascular graft 
infections is usually made on the basis of clinical findings, 
supported by radiological and microbiological investigations. 
As for infections of implanted material, it is recommended 
to replace the vascular prosthesis so as to eradicate 
the infection while preserving or restoring arterial 
vascularization. Various replacement vascular materials (in 
situ or extra-anatomic) are available such as antibiotic or 
silver coated vascular prostheses, autologous or heterologous 
venous or arterial grafts.2 More recently, the trend has been 
to move away from graft removal to graft preservation with 
the use of vacuum assisted closure (VAC) devices, with or 
without muscle flap coverage more commonly employed.5 We 
examined our experience with infected prosthetic grafts 
after surgical bypass and the impact of postoperative graft 
infection on amputation rates and mortality.
Material and methods
In order to summarize our centre s´ experience, we 
retrospectively reviewed the clinical files of vascular graft 
infections implanted at the department of Angiology and 
Vascular Surgery at Coimbra´ s University Hospital Center, 
from 01.06.2007 to 31.12.2011, and analysed the cases of 
PVGI identified until 31.12.2012. We defined a graft infection 
as clinical e laboratory evidence of infection associated 
with the presence of fluid directly communicating with 
the graft (in an imagiological or intra-operative view) or an 
exposed graft. We excluded arteriovenous and endovascular 
grafts; grafts implanted in another institution; bypass grafts 
performed for management of previous PVGI and infections 
categorized in Samson group 1 or 2. Once all the clinical 
files were identified, an individual detailed questionnaire 
was completed with the study data. Patient demographics, 
body mass index, comorbidities, indications for intervention, 
location of bypass, type of prosthetic material, case urgency, 
and previous ipsilateral bypass or percutaneous interventions 
were recorded as well as the timing of infection, diagnosis, 
bacteriology, treatment and outcome. 
Results
Between 01.06.2007 and 31.12.2012, a total of 18 patients 
with PVGI that met the inclusion criteria were admitted to 
our department. During the study period 480 prosthetic 
grafts were implanted, accounting for a 3.8% incidence 
of PVGI (Tables 1 and 2). Subjects are ranged from 28 to 
82 years (average age 70.4 ± 12.61 years) and the male/
female ratio was 14:4. The most prevalent risk factors were 
Diabetes Mellitus (44%), tissue loss (44%), previous arterial 
puncture (44%) and previous ipsilateral incision (55%). 
Thirteen revascularization procedures were performed in 
Infeções vasculares prótesicas: A experiência de um centro
Resumo
Introdução: A infeção de enxertos protésicos vasculares é uma complicação grave da cirurgia 
vascular, cursando com altas taxas de morbimortalidade. Este estudo retrospetivo não 
randomizado, unicêntrico, avaliou a sua experiência na gestão de infeções de próteses vasculares.
Métodos: Fez-se uma revisão dos processos clínicos das revascularizações protésicas vasculares 
realizadas no nosso centro entre junho de 2007 e dezembro de 2011 e selecionaram-se aquelas 
que desenvolveram infeções do grupo 3, 4 e 5 da classiÀ cação de Samson até dezembro de 2012.
Resultados: Desde junho de 2007 a dezembro de 2012, 18 doentes (14 homens, 4 mulheres), com 
uma média de idade 70 anos, foram admitidos no nosso centro com o diagnóstico de infeções de 
próteses vasculares contribuindo para uma incidência de 3,8%. 50% das infeções foram precoces 
sendo o MRSA o patogéneo mais isolado. 44% das infeções deveram-se a infeção de conduto 
femoro-poplíteo. Usando a classiÀ cação de Samson, 72% foram infeções grupo 4 e 5. Realizámos 
preservação do enxerto num doente, excisão da prótese sem revascularização em 50% (nove) 
doentes; Excisão + substituição in situ em 39% (sete) doentes; Excisão + bypass extra-anatómico 
num doente. A nossa taxa de amputação foi de 55% e a nossa mortalidade relacionada foi de 16%.
Conclusões: As taxas de amputação e mortalidade da série estão de acordo com as revisões 
publicadas previamente. Para além de permitir reconhecer a nossa realidade esta publicação 
oferece a oportunidade de rever o diagnóstico e questões terapêuticas relacionadas com 
infeções de enxertos vasculares protésicos. Cada situação deve ser individualizada, pois não 
há consenso nem protocolos estabelecidos sobre qual deve ser o tratamento de eleição.
© 2014 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Publicado por Elsevier España, S.L. 
Todos os direitos reservados.
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ten patients before the implantation of the graft. Only two of 
these 13 revascularizations consisted in prosthetic material 
(occluded ABFP due to precarious outflow, supplemented 
with femoro-popliteal reconstruction). 33% of the grafts 
were implanted in an emergent setting. 55% of grafts were 
used for management of failed previous revascularization 
(Table 3) and for arterial occlusive disease in 28% (5/18). 
22% (4/18) consisted of polyethylene terephthalate (Dacron) 
material and 78% of polytetrafluoroethylene (PTFE).
After implantation of the graft, redo bypass was performed 
in a total of 33% (6/18) patients, of which, 3 during the same 
time hospitalization and 3 in a different hospitalization 
(interval of 30 to 275 days). Again these 3 procedures 
were performed due to thrombosis, with purpose of limb 
salvage. There was an 11% incidence of wound infection and 
33% of surgical sutures dehiscence. Limbs underwent ulcer 
debridement/minor amputations in 33% of the cases all at 
the initial hospital stay.
The diagnosis of PVGI was established by patient 
history, clinical examination (Table 4), laboratory tests 
(C-reactive protein, leucocytosis), microbiologic profile, 
ultrasonography (USG), computed tomography (CT). Using 
Samson classification, 6 cases were grade V, 7 cases grade 
IV, and 5 cases grade III.
The mean period from the primary intervention to the 
occurrence of infection was on average 8.1 ± 11.7 months. In 
9 cases it was an early infection (within the first 4 months). 
44% (8) of infected grafts consisted of femoro-popliteal 
bypass. Most patients (72%) had an imagiological 
confirmation of infection (CT by 60%). Bacterial culture was 
available in 100% patients (28% from wound exsudate, 38% 
from intra-operative peri-graft liquid and 72% from culture 
of the graft). Staphylococcus organisms (Staphylococcus 
aureus (16%), Methicillin-resistant Staphylococcus aureus 
(50%)) were detected most often, followed by Gram 
negative organisms (Pseudomonas aeruginosa, Klebsiella, 
Morganella) in 33%, Enterococcus (16%) and anaerobic spp 
in 1 case. In 17% of the cases, a polymicrobial infection was 
present. No patient was treated with antibiotics before 
hospital admission due to symptoms of graft infection. All 
the patients were treated empirically with antibiotics after 
admission, and after bacteriology results, they were treated 
according to the sensitivity. The antibiotherapy was applied 
for the minimum period of 2-6 months (mean duration of 
intravenous antibiotics: 30.38 days).
At the time of admission, 50% of the grafts were patent. 
We performed preservation of the prosthesis with radical 
surgical surgical debridement in one patient (Samson 
3 infected aorto-bifemoral bypass without involvement of 
the graft body), extirpation in 50% cases, in situ bypass 
with autologous vein in 22%, cadaveric vein in 22% and 
with graft in 5.5%. In the preserved graft we used local 
rotational muscle flap closure with Sartorius muscle. During 
the management of the infected bypass, each patient 
underwent a mean of 2.4 surgical procedures.
The mean follow-up was 2 years. We had to perform a major 
amputation in 55% of patients (Table 5). Two patients, who had 
an above-knee amputation, had recurrent infections requiring 
further debridement. The preserved graft was successfully 
salvaged. Some patients who required graft removal had no 
reconstructive options or the limbs were not salvageable at 
the time of presentation with PVGI. In the group that had a 
Table 1 Demographic data.
June 1 2007-December 31 2012
n 18
Average age 70.4 ± 12.61 years
Ratio men: women 14:4
Primary vascular reconstruction 
 (infected/total)
 Aorto-(bi)-femoral 2/135 (1.5%)
 Femoral-femoral 1/47 (2.6%)
 Femoral-popliteal 8/69 (11.6%)
 Axillary-femoral 4/14 (28.6%)
 Others 3/215 (1.4%)
Time from de primary reconstruction 
 to the infection:
8.1 ± 11.7 months
Functional infected reconstruction 9 (50%)
Table 2 Patient characteristics (No. (%)).
Female gender  4 (22%)
Obese (BMI >30)  2 (11%)
Pulmonary obstructive disease  2 (11%)
Coronary artery disease  4 (22%)
Diabetes mellitus  8 (44%)
Hypertension  2 (11%)
Chronic renal insufÀ ciency  2 (11%) 
Smoker  6 (33%)
Trophic lesions  8 (44%)
Prior percutaneous access  8 (44%)
Redo bypass 10 (55%)
Emergent implantation  6 (33%)
BMI, body mass index.
Table 3 Indication for revascularization.
Aorto-iliac disease 4 (22%)
Femoro-popliteal disease 1 (5.5%)
Aortic Aneurysm 2 (11%)
Femoral Pseudoaneurysm 1 (5.5%)
Thrombosis of FP w/ GSV 5 (27%)
Thrombosis after Femoral profundoplasty 3 (16%)
Early occlusion of ABFP limb 2 (11%)
ABFP, aorto-bi-femoral bypass; FP, femoro-popliteal; GSV, 
great saphenous vein.
Table 4 Clinical À ndings associated with prosthetic 
vascular graft infections (n =18).
Abscess 12 (66%)
Fever  4 (22%)
Anastomotic pseudoaneurysm  3 (16%)
Bleeding  4 (22%)
Septical embolization  0
Sepsis  0
Atypical presentation: Dyspepsia, pain, 
 fatigue, weight loss
 0
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patent graft and underwent excision without revascularization 
(3 cases), 67% (2/3) had limb salvage. The global mortality 
was 33% (6 patients) – three cases of sepsis and three not 
related deaths (oral cancer, one acute myocardial infarction, 
one splenic infarction). Two of the three related deaths were 
Samson group 4 and the remaining Samson group 5. In the three 
fatalities MRSA was isolated (in two with co-associated Gram 
negative bacteria: Pseudomonas + Morganella multiresistent). 
17% were lost to follow-up.
Discussion
Prosthetic aortic graft infections represent a major 
diagnostic and therapeutic challenge.6 The leading cause 
of graft infection is contamination at the original surgical 
procedure. Emergency surgery, poor sterile technique, 
bowel injury during the operation, extensive lymphatic 
manipulation or injury during the dissection, extended 
preoperative hospital stay predisposing the patient to 
virulent pathogens and prolonged operating time are 
frequent predisposing factors for graft infections.7 The 
presence of an active infection at the time of the operation 
is predictive of Surgical Site Infections (SSIs) and prosthetic 
graft infection, most likely owing to contamination during 
the procedure or perioperative period. In our case series 
44% of cases had trophic lesions in the limbs. Siracuse et 
al., in their retrospective study about prosthetic graft 
infections involving the femoral artery concluded that redo 
bypass, female gender, diabetes, and active infection at the 
time of bypass are associated with a higher risk for graft 
infection, which results in subsequent early major extremity 
amputation.5 A redo operation was also predictive of graft 
infection, likely secondary to scarring and poor vascular 
supply. On our series, 33% of the patients needed a redo 
revascularization after implantation of the prosthesis. Of 
these six patients, 5 (83%) ended up with limb loss.
According to Edwards et al., surgical wound complications 
(skin necrosis, hematoma, seroma e cellulites) are identified 
as primary predisposing factors in 33% of PVGI. More than one 
third of infections had previous wound complications.8 In our 
case the incidence of wound complications was 39% (7/18).
Another factor playing a role in aortic graft infections 
may be the type of prosthetic graft material used for repair. 
There is probably no significant difference in the incidence 
of infection of Dacron grafts compared with PTFE grafts. 
However, after infection develops, Dacron grafts may 
be more resistant to eradication of infection than PTFE 
grafts and Dacron may be more commonly associated with 
systemic sepsis and anastomotic disruption.7
The authors found a PVGI incidence of 3.8% in their 
cohort. But it had into account intracavitary prosthesis 
(149 interventions). If we exclude these procedures the 
adjusted incidence increases to 5.5%. Surprisingly the authors 
found that 30% of axillary-femoral conducts (4/14), a high 
incidence compared to literature (4.1%). In what concerns 
the four axillary-femoral grafts infections, it is known that 
subcutaneous tunnels increase the risk of PVGI. Also, this 
kind of vascular reconstruction is usually performed in poor 
functional capability patients. Three cases were perform 
secondary to aorto-iliac disease without physical conditions 
to perform an abdominal bypass and the forth case was after 
a femoral thromboendarterectomy that failed.
Avoidance of a prolonged preoperative hospital stay 
to minimize the development of skin flora resistant to 
commonly used antibiotics (i.e., hospital-acquired strains) 
is important.7,8 It is critical that intravenous antibiotics 
be administered within 1 hour of the skin incision. 
Administration of antibiotics before this time is of no 
benefit and may actually be harmful by predisposing to 
resistant antibiotics.7 They should be administrated during a 
prolonged surgery or when huge changes in vascular volume 
occur.8 Intravenous antibiotics after surgery is controversial. 
There are no sound data to prove that they should be 
continued more than 24 hours for routine cases.7 Longer 
duration of perioperative antibiotics (>48 hours) may be 
considered whenever patients present more than two risk 
factors for wound infection, including extremes of age, 
malnutrition, chronic illnesses such as diabetes, remote 
infections or prior irradiation of the surgical site.9
The most common bacteria cultured from infected grafts 
include Staphylococcus aureus, Staphylococcus epidermidis, 
diphtheroids, and gram-negative enteric organisms.7 In the 
past 2 decades, the incidence of MRSA has greatly increased, 
and it has become an important pathogen, contributing 
to 33% of vascular SSIs. In our series it represents a 50% 
contributing pathogen. Graft infections associated with 
negative culture results are caused by S. epidermidis or other 
coagulase-negative staphylococci, or by Candida species. 
Infections due to Gram-negative bacteria like E. coli, 
Pseudomonas, Klebsiella, Enterobacter and Proteus spp are 
very virulent9 compared with low virulence organisms such 
as coagulase negative Staphylococcus, Corynebacterium, 
or Propionibacterium species.10 In patients with a reduced 
immunity, serious mycotic graft infections may occur 
(Candida, Mycobacterium, Aspergillus).11
Table 5 Treatment and major complications of the prosthetic vascular graft infections.
Amputation Mortality
  Related Not related
Preservation + Debridement 0% (0/1) 0% (0/1) 0% (0/1)
Excision without  revascularization 55% (5/9) 0% (0/9) 11% (1/9)
In situ with vein 66% (4/6) 33% (2/6) 16% (1/6)
In situ with graft 100% (1/1) 100% (1/1) 0 % (0/1)
Extra-anatomical reconstruction 0% (0/1) 0% (0/1) 100% (1/1)
TOTAL 55% (10/18) 16% (3/18) 16% (3/18)
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Clinical manifestations of PVGIs are variable and can range 
from an apparent superficial wound infection to a potentially 
life-threatening complication such as hematochezia due 
to an aortoenteric fistula. Patients presenting with an 
early-onset PVGI may only present with a superficial surgical 
wound infection. Systemic manifestations of infection such 
as fever, hypotension, and tachycardia are more frequent 
with more virulent organisms such as S. aureus and P. 
aeruginosa. However, other local complications such as 
perigraft abscess, anastomotic aneurysm, hemorrhage, 
and poor incorporation of the graft into surrounding tissue 
may be encountered. Lower extremity prosthetic vascular 
grafts may even be exposed to the outside. Moreover, 
graft occlusion and distal septic emboli may result in tissue 
ischemia and/or gangrene.10
Most cases of late PVGI have no general symptons.11 Local 
signs of a smoldering infection such as poor incorporation 
of the graft into surrounding tissues, sinus tract formation, 
graft occlusion, pseudoaneurysm formation, and 
aortoenteric fistula are more frequent.10
The basic diagnostic indicators, apart from clinical 
examination and patient’s history, are increased levels of 
leucocytes, CRP, sedimentation and positive bacteriological 
culture from the site of the vascular infection and a positive 
hemoculture. TC should be the first image exam whenever 
there is a suspicion of aortic graft infections. USG is a 
first line exam to evaluate superficial grafts and inguinal 
tumefactions.12 Ultrasound guidance with findings of the 
accumulation of fluid around the vasculature reconstruction 
and false aneurysm in anastomosis, as well as CT and MRI have 
a high sensitivity and specificity for PVGI. Suspected PVGI on 
CT or MRI can be identified by a free prosthesis with no signs 
of healing in the surrounding tissue, by the accumulation of 
fluid with gas bubbles around the vascular reconstruction, 
tissue swelling around reconstruction and false anastomotic 
aneurysm. Using the mentioned examinations, in the absence 
of clinical manifestation, it is difficult to distinguish the early 
PVGI from post-operative changes, simple hematoma and 
the presence of gas after surgery,11 which can be a normal 
postsurgical finding up to 3 months after the procedure 
in cases of liquid collections and up to 1 week in case of 
air pockets.10 White blood cell scanning is an important 
complementary test to CT in ambiguous cases, such as in 
the early postoperative period, and may be more sensitive in 
detection of early graft infection.13
Four basic principles involved in the management of PVGI 
include 1) complete excision of all infected material; 2) 
extensive debridement of the infected and necrotic tissue 
in the perigraft area; 3) appropriate antimicrobial therapy 
based on identification of the causative organisms; and 4) 
restoration of the distal blood supply.7,10
Intraoperative tissue specimens should be submitted 
to the microbiology laboratory for bacterial (gram stain), 
fungal and mycobacterial stains and cultures.10 While 
awaiting the culture results, empiric broadspectrum 
antibiotic therapy that includes coverage for resistant gram 
negative and gram-positive organisms including methicillin 
resistant staphylococci should be initiated. Empiric use of 
carbapenems may be considered in institutions with a high 
prevalence of extended-spectrum b-lactamase–producing 
gram-negative organisms.10 In our series 77% (14/18) 
were treated empirically with vancomycin and in 50% 
of the cases there was an association with carbapenems 
(imipenem). Until recently daptomycin was not available 
in our institution. The characteristics of daptomycin (rapid 
and intense bactericidal action including on bacteria with 
low metabolism, diffusion in the biofilm) at strong doses 
make it a good agent for the treatment of VPIs.12 For 
cases where intra-abdominal graft infection from a 
gastrointestinal source is a consideration, empiric anaerobic 
coverage should also be added. Empiric antifungal or 
anti-mycobacterial coverage is generally not needed. In 
general, a minimum of 4 to 6 weeks of systemic antibiotic 
therapy is recommended10,11 and subsequent oral therapy 
for the period 3-6 months.10 For our statistical analysis, total 
duration of antibiotic therapy was not possible to collect 
because after the initial intravenous therapy there is a 
scarce information on medical records about ambulatory 
oral antibiotics as well as its total duration. 
The surgical therapeutic options are: Graft preservation; 
Graft excision without revascularization; Excision + in-situ 
replacement; Excision + Extra-anatomic bypass.9 Success 
of graft or route salvage is often determined by the 
infective organism, with pseudomonas and MRSA infected 
grafts being particularly difficult to salvage.14 The current 
literature indicates Samson group 3 patients are most 
often considered for graft salvage and route salvage (in 
situ reconstruction)12,14 with partial or total preservation of 
graft. Patients limited to Samson group 4 and 5 normally 
need complete excision of the graft. The current literature 
suggests that MRSA-infected graft preservation should 
only be attempted with minor graft involvement. The high 
proportion of amputations is likely due to the prevalence 
of MRSA and the excision of the graft in a population with 
already threatened limbs.12,14 The rate of amputation in MRSA 
group was 66% (6/9) and the remaining 22% need aggressive 
tissue excision with cutaneous flaps.
Excision of the infected reconstruction with a large scale 
debridement is only possible in patients who, as a result of 
PVGI, have developed thrombosis of the reconstruction with 
sufficient collateral circulation. Even then it is associated 
with a high number of amputations.11
In situ reconstruction can be accomplished by using 
three different types of graft materials: autogenous vein 
grafts, cryopreserved or fresh arterial allografts and 
antibiotic-bonded prosthetic grafts. Arterial and vein grafts 
have the benefit of lower re-infection rates compared with 
prosthetic grafts. Vein grafts have the added advantage 
of higher long-term patency rates compared with the 
arterial grafts.10 On four patients we used cryopreserved 
veins: in two as a single option and the other two because 
of failed great saphenous vein bypass. 3 of these resulted 
in amputation and in the remaining we had to perform 
excision of the cadaveric vein due to inguinal dehiscence 
and exposition of the vascular role. For antibiotic bonded 
prosthetic vascular grafts, rifampicin is the most commonly 
used antibiotic to coat grafts. There is also a silver coated 
prosthesis which demonstrate a very good healing ability in 
tissue.11
Extra-anatomic bypass graft was traditionally considered 
the gold standard procedure because it avoids placing a 
new graft in a previously infected surgical bed. However, 
results of a systematic review in 2006 revealed that overall 
rate of reinfection, amputation, conduit failure, and 
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mortality was slightly lower in patients who underwent in 
situ reconstruction compared with extra-anatomic bypass 
surgery.10 Staged procedure may be chosen in order to 
minimize a reinfection of the new vascular reconstruction. 
Some authors prefer the simultaneous procedure as some 
clinical results did not support this approach.11
There are several limitations to our study. It is a single 
center retrospective review, in a short period of time (June 
2007 and December 2011). There was no standardization for 
the choice of conduit; rather, it was surgeon dependent and 
based on personal preference, which could cause selection 
bias because patients who are viewed as high risk may have 
more vein options exhausted before using a prosthesis.
Either way the authors can conclude that graft infections 
can assume a catastrophic development with serious 
sequelae such as limb loss and can be lethal. In summary, 
therapeutic procedures in PVGI must not be generalized, 
as every patient with a PVGI requires a strictly individual 
approach in order to select the best therapeutic procedure.
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